Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our country websites.
-
GSK delivers improvements in sales, margins and cash flow in 2017
Total EPS 31.4p, +67% AER, +36% CER; Adjusted EPS 111.8p, +11% AER, +4% CER
Read more -
GSK’s meningitis B vaccine Bexsero receives Breakthrough Therapy Designation from US FDA for prevention of Invasive Meningococcal Disease in children 2-10 years of age
GlaxoSmithKline plc announced that it has received Breakthrough Therapy Designation from the U.S. FDA for its meningitis B vaccine Bexsero
Read more -
GSK’s Shingrix receives positive opinion from the CHMP in Europe for the prevention of shingles in adults aged 50 and over
Shingrix is a non-live, recombinant subunit adjuvanted vaccine given intramuscularly in two doses, with a two-to-six month interval between doses.
Read more -
GSK announces CHMP positive opinion for labelling update to Relvar Ellipta in patients with asthma
A positive CHMP opinion is one of the final steps before marketing authorisation is updated by the European Commission.
Read more -
GSK responds to the AMR Benchmark
The new AMR Benchmark provides a useful analysis of the industry’s contribution to addressing the severe public health threat of antimicrobial resistance
Read more -
FDA approves US label update on ICS/LABA combinations in asthma, based on review of safety data
Boxed warning removed from ICS/LABA combination products, including BREO ELLIPTA, ADVAIR DISKUS and ADVAIR HFA.
Read more -
GSK submits regulatory application for single-dose tafenoquine for the treatment of Plasmodium vivax malaria to Australia’s Therapeutic Goods Administration
Innovative science drives progress in developing medicines for infectious diseases.
Read more -
GSK achieves approval for Nucala (mepolizumab) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) for adults in the US
First targeted treatment approved for this rare eosinophil-driven disease
Read more -
GSK presents promising new data for priority BCMA asset from its emerging Oncology pipeline at 59th ASH meeting
Data from dose expansion phase of DREAMM-1 study
Read more -
New data supports the safety and efficacy of GSK’s Shingrix in preventing shingles in autologous haematopoietic stem cell transplant patients
New data supports the safety and efficacy of GSK’s Shingrix in preventing shingles in autologous haematopoietic stem cell transplant patients
Read more -
GSK welcomes launch of the UK Government’s Life Sciences Sector Deal
New £40 million GSK investment in genomic research
Read more -
ViiV Healthcare announces start of phase III study of long-acting cabotegravir for HIV prevention in women
The HPTN 084 study will evaluate injections given every two months
Read more -
GSK submits US regulatory application for single-dose tafenoquine for Plasmodium vivax malaria
Regulatory milestone affirms GSK's strong commitment and scientific capabilities to fighting infectious diseases
Read more -
GSK responds to UK Industrial Strategy
Read our response to the UK Industrial Strategy White Paper.
Read more -
ViiV Healthcare starts third phase III HIV treatment study investigating long-acting two-drug regimen of cabotegravir plus rilpivirine
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced the start of a phase III study with a ...
Read more -
GSK submits landmark IMPACT data to US regulatory authority to support expanded label for Trelegy Ellipta
GSK submits landmark IMPACT data to US regulatory authority to support expanded label for Trelegy Ellipta
Read more -
Juluca® (dolutegravir and rilpivirine) approved in US as first 2-drug regimen, once-daily, single pill - a complete regimen for the maintenance treatment of virologically suppressed HIV-1 infection
ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food an...
Read more -
Trelegy Ellipta once-daily single inhaler triple therapy gains marketing authorisation in Europe for the treatment of COPD
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has granted marketing authorisation for Trelegy Ellipta
Read more -
GSK receives European marketing authorisation for self-injectable formulation of Benlysta for the treatment of systemic lupus erythematosus
The approval is for a single-dose prefilled syringe and a single-dose prefilled pen (autoinjector) presentation, administered as a once weekly injection of 200mg.
Read more -
Patrick Vallance, President, R&D, GSK to become UK Government's Chief Scientific Adviser
Patrick Vallance, President, R&D, GSK to become UK Government’s Chief Scientific Adviser
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products through to life-saving medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines and consumer healthcare from inside and outside our labs.
